SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
MAZE

Maze Therapeutics, Inc. (NASDAQ:MAZE)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$31.37-$1.06 (-3.27%)
 
Market cap
$1.72B
Insider Score
Health Score
Analyst consensus
Listed since
Jan 31, 2025
Website
Market Cap$1.72B-14.4%
Revenue (ttm)$20.00M
Net Income-$151.47M-20.1%
EPS-$2.87-25.3%
Shares Out54.68M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume818,930
Open$31.70
Previous Close$32.43
Day's Range$31.10 - $32.72
52-Week Range$21.95 - $53.65
Beta2.03
AnalystsBuy
Price Target$75.00(+139.08%)
Earnings DateMar 24, 2027

About MAZE

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Address
171 Oyster Point Blvd, South San Francisco, CA, 94080, US
Market Cap
1.72 billion
Employees
141
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$4.20M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy0 Hold0 SellAvg target $57.00 (+82.7%)

4 firms rating MAZE in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From MAZE’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-3.27%
5 Days
-9.75%
1 Month
-1.82%
6 Months
+21.68%
1 Year
-14.43%

$MAZE stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in MAZE holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by MAZE's directors and management

Net Shares Purchased by Insiders−100k−50k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

MAZE Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New MAZE patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to MAZE from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in MAZE

VTIVanguard Morningstar Total Stock Market ETF$35.04M
IWMiShares Russell 2000 ETF$29.66M
VXFVanguard Extended Market ETF$13.29M
XPHState Street SPDR S&P Pharmaceuticals ETF$12.64M
IWOiShares Russell 2000 Growth ETF$9.08M
IBBiShares Biotechnology ETF$8.33M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from MAZE’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
24
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-38.0 since Aug 21
0255075100Aug 21 — Insider Score 38.0Aug 22 — Insider Score 38.0Aug 23 — Insider Score 38.0Aug 24 — Insider Score 38.0Aug 25 — Insider Score 37.0Aug 26 — Insider Score 37.0Aug 27 — Insider Score 37.0Aug 28 — Insider Score 37.0Aug 29 — Insider Score 37.0Aug 30 — Insider Score 37.0Aug 31 — Insider Score 37.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 25.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

XPHState Street SPDR S&P Pharmaceuticals ETF2.60%
SBIOALPS Medical Breakthroughs ETF1.31%
BBCVirtus Biotech Clinical Trials ETF1.13%
PILLDirexion Daily Pharmaceutical & Medical Bull 3X ETF0.38%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.34%
FYCFirst Trust Small Cap Growth AlphaDEX Fund0.33%
IWCiShares Micro-Cap ETF0.32%
IHEiShares U.S. Pharmaceuticals ETF0.27%
SCDSJPMorgan Fundamental Data Science Small Core ETF0.25%
IBBQInvesco Nasdaq Biotechnology ETF0.13%
IBBiShares Biotechnology ETF0.09%
BIBProShares Ultra Nasdaq Biotechnology0.08%

Weight is the stock’s share of each fund’s holdings.